<DOC>
	<DOCNO>NCT00003564</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know whether give procarbazine alone isotretinoin effective recurrent primary malignant glioma . PURPOSE : Randomized phase III trial compare effectiveness procarbazine alone isotretinoin treat patient recurrent primary malignant glioma .</brief_summary>
	<brief_title>Procarbazine Isotretinoin Treating Patients With Recurrent Primary Malignant Gliomas</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether combination isotretinoin procarbazine improve time progression survival compare procarbazine alone patient recurrent malignant glioma . II . Document toxicity two regimens patient . OUTLINE : This randomize , multicenter study . Patients randomize receive procarbazine alone combination isotretinoin . Arm I : Patients receive oral procarbazine daily day 1-14 every 28 day . Oral isotretinoin administer every 12 hour day 15-28 every 28 day . Patient receive 6 course combine therapy , continue oral isotretinoin alone day 15-28 28 day course , disease progression unacceptable toxicity . Arm II : Patients receive procarbazine mouth daily day 1-14 follow 2 week rest . Patients receive total 6 course treatment absence disease progression unacceptable toxicity . Patients follow death . PROJECTED ACCRUAL : This study accrue total 194 patient ( 97 per treatment group ) .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven primary malignant glioma include follow : Glioblastoma multiforme Gliosarcoma Anaplastic astrocytoma Anaplastic oligodendroglioma Anaplastic infiltrate glioma Mixed malignant glioma Must show evidence tumor recurrence progression least 2 serial enhance MRI scan Must measurably enhance residual disease MRI CT scan brain PATIENT CHARACTERISTICS : Age : 16 Performance status : Karnofsky 60100 % Life expectancy : Greater 8 week Hematopoietic : Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : SGPT le 2 time institutional normal Alkaline phosphatase less 2 time institutional normal Bilirubin le 1.5 mg/dL Renal : BUN le 1.5 time institutional normal OR Creatinine le 1.5 time institutional normal Other : No active infection Not pregnant nursing Fertile patient must use effective contraception 1 month , , 1 month study No disease obscure toxicity alter drug metabolism No concurrent medical illness PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior procarbazine No prior isotretinoin At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) recover Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy allow Surgery : Not specify Other : No concurrent tetracycline</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>